Efficient selection of gene-modified cells is required for a number of potential gene therapy applications, as well as molecular biology studies. Ideally, a clinical selection regimen would combine high selection speed, efficiency and efficacy, in addition to clinical grade selection techniques and low immunogenicity. To our knowledge, a selection marker satisfying all these features is so far not available. Ouabain is a clinically used cardiac glycoside and selective Na its resistance to ouabain. Two amino-acid substitutions, Q118R and N129D were sufficient to confer a two log greater resistance to ouabain in HeLa, Jurkat, U2OS cells and in primary cells. Furthermore, following transduction of primary lymphocytes with the a1 Q118R/N129D gene, 499% pure populations of gene-modified cells were achieved with a recovery rate of 480% after 48 h of exposure to ouabain. These results identify the human a1 Q118R/N129D (OuaSelect) as a promising selection marker gene for safe, rapid and cost-effective selection in clinical gene therapy and molecular biology research.
Introduction
Gene therapy has potential as an approach to address unmet medical needs of patients with genetic or acquired diseases. However, complex biological and technical challenges need to be resolved for this delivery platform to translate into successful clinical protocols. Among these challenges, gene delivery has been described as 'the Achilles heel of gene therapy'. 1 To achieve the desired clinical effect of cells manipulated ex vivo, a selection step to enrich the successfully modified target cell population could be necessary. For certain applications, such as T-cell suicide gene therapy, the selection efficiency is pivotal, since unmodified cells will escape suicide gene activation.
Positive selection markers depending on the use of toxic agents, such as antibiotics, were the first to be developed and exploited. In general, such drug-resistance selection strategies are highly efficient, but require selection times amounting to several days. In the clinical setting, including a long-lasting selection step is undesirable as it significantly prolongs the ex vivo gene-transfer process. Long-term culturing has clearly been demonstrated to induce alterations in critical cell functions. [2] [3] [4] [5] Moreover, prokaryotic genes, such as the neomycin phosphotransferase II (NeoR) gene, are not suitable for clinical applications because they are highly immunogenic. 6, 7 Another concern is selection toxicity, as with the NeoR selection agent G418, which is toxic to primary cells. 8 Furthermore, several human genes have been exploited in chemoprotective gene therapy and can facilitate chemotherapeutic drug selection. [9] [10] [11] However, the intrinsic risk of causing genotoxic damage to cells limits the application of chemotherapeutic drugs for ex vivo selection. Thus, the extensive selection time, and risk for toxicity and immunogenicity make current drug selection markers suboptimal for clinical use.
Today, candidates for clinical selection markers are wild type and engineered human plasma membrane proteins. The low-affinity nerve growth factor receptor with a cytoplasmic deletion (dLNGFR) 12 is frequently used for retroviral gene transfer to hematopoietic cells. 6, 13, 14 Other surface molecules such as a CD34 splice variant (tCD34), 15 CD90 (Thy-1) 16 and CD20 17 have also been developed and are under investigation for applicability and safety. All of the above present the advantages of minimized risk for immunogenicity and rapid cell sorting procedures using magnetic beads. However, large-scale cell sorting with magnetic beads under good manufacturing practice (GMP) is costly. A proportion of gene-modified cells is also adversely lost in the process. Moreover, concerns regarding context-dependent side effects due to ectopic full-length or truncated surface marker expression interfering with cellular signaling networks or disturbing homing patterns remain and require further exploration. 18, 19 Improvements of ex vivo gene-modification procedures necessitate the development of new selection marker genes that fulfill the stringent criteria of safety and feasibility that clinical applications demand. Here, we describe the development of a human ouabain-resistant Na + /K + -ATPase a1 subunit that with only two aminoacid substitutions allows for efficient selection of genemodified cells within 48 h of drug exposure. The ouabain selection agent provides high recovery rates and costeffective selection. Moreover, cardiac glycosides such as digoxin, digitoxin and ouabain have been used for two centuries in the treatment of congestive heart failure with no sign of toxicity other than specific inhibition of Na + /K + -ATPase activity. 20 Therefore, this selection marker gene could offer an improved selection regimen to be evaluated in view of existing in vitro and ex vivo selection markers in use for clinical gene therapy and basic research.
Results

Human and rat chimeric a1 subunits
The human and rat a1 polypeptides are 98% identical, yet demonstrate highly different sensitivity to ouabain (K d of 5 Â 10 À5 and 1 Â 10 À8 M, respectively). 21 A single point mutation in the rat a1 subunit, L799C, further augments its resistance to ouabain. 22, 23 To identify regions of the rat a1 subunit that confer ouabain resistance to chimeric human a1 subunits, full-length chimeras of the human a1 and the rat a1 L799C (OuaR) genes were generated. The chimeric genes were expressed as green fluorescent protein (GFP) fusion proteins in transiently transfected HeLa cells. Twenty-four hours post-transfection, the cells were exposed to 10 À5 M ouabain for 24-48 h and subsequently evaluated for GFP expression and survival. The first chimeric crossover point was located at amino-acid position 130, immediately after the first extracellular domain. All ouabain-resistant constructs contained the N-terminal rat sequence, while all constructs with a human N terminus were sensitive to 10 À5 M ouabain ( Figure 1 ). The results revealed that replacing the first 130 amino acids in the human a1 polypeptide with the rat sequence bestowed resistance to 10 À5 M ouabain.
N-terminal amino-acid substitutions in the human a1 subunit
In the next step, the role of specific amino-acid positions to ouabain resistance was examined. Within the Nterminal 130 amino acids, 10 amino-acid changes are present in the human a subunit compared to the rat a subunit. Since ouabain binds to the extracellular surface of the a subunit, we only targeted the four extracellular and not the six intracellular amino-acid positions within the predicted intracellular region. Thus, the human to rat substitutions Q118R, A119S, Q126P and N129D of the human a1 subunit were made by site-directed mutagenesis individually or in combination. The functional effect was determined in transfected HeLa cells by means of conferring resistance to 10 À5 M ouabain. Some additional substitutions were tested at positions 118 and 129, but these did not confer resistance. Hence, the substitutions Q118R and N129D were sufficient and required for resistance to 10 À5 M ouabain (Table 1) . For simplicity, the mutated human a1 Q118R/N129D is hereafter termed OuaSelect.
Identification of OuaSelect subcellular localization
Assembly of the a-subunit with the cognate b-subunit is required for the a-subunit to become functionally active and expressed at the plasma membrane. 24, 25 The GFP fusion constructs enabled identification of the subcellular localization of the OuaSelect protein. Both human native a1 and OuaSelect localized to the cell surface (Figure 2a) , indicating proper heteromerization of OuaSelect with the endogenous b-subunit. The results suggest that protein trafficking is not perturbed by the mutations in OuaSelect.
Ouabain selection of transiently transfected cells
Transient transfection is a powerful method to study the function of genes and non-coding DNA. However, the variable rate of transfection can complicate interpretation of functional readouts. Such an uncertainty can be overcome by accounting for fluorescent marker coexpression, but methods to rapidly eliminate untransfected cells would be advantageous in some experimental setups. Therefore, ouabain selection was evaluated in a transient co-transfection assay. Osteosarcoma U2OS cells were transfected with either a GFP-OuaSelect plasmid or with two plasmids expressing either OuaSelect or GFP. Ouabain resistance was observed in both cases (Figure 2b ). The addition of a plasmid expressing short-hairpin RNA (shRNA) against GFP 26, 27 resulted in a strong downregulation of green fluorescence. It was associated with a loss of resistance in GFP-OuaSelect expressing cells, while it was retained in cells in which OuaSelect and GFP were expressed from different plasmids. In summary, selection with ouabain can mediate cost-effective purification of transiently transfected cells without the requirement of cumbersome cells sorting. Further, the shRNA experiment substantiated that OuaSelect is indeed responsible for conferring resistance to ouabain. -ATPase a1 genes. The upstream points I and II were generated by PCR and overlapping oligo primers, while the shared recognition sequences for PpuMI and PflMI were used for downstream crossover points. The L799C mutation (*), the position of the first extracellular domain (**), and human (white) and rat (black) sequence segments are indicated. HeLa cells transiently transfected with pC1-eGFP-native a1 fusion protein (1) or pC1-eGFP-chimeric sequences 2-5 were eliminated with 24 h of incubation in 10 À5 M ouabain. Cells transfected with pC1-eGFP-rat a1 L799C (6) and the pC1-eGFP-chimeric sequences 7-11 were resistant and survived 24-h exposure to 10 À5 M ouabain. 
Rapid and efficient cell selection with OuaSelect
Transduction and selection with OuaSelect retrovirus vectors
For numerous therapeutic gene transfer approaches, stable long-term expression is a prerequisite and is achievable by retroviral vector integration. Therefore, OuaSelect transgene expression and function was tested by retroviral transfer. Jurkat cells were transduced with GFP (SF-G) or GFP-OuaSelect (SF-GO) viral supernatants with an multiplicity of infection (MOI) of 1.5. The mean transduction rate was 41% for SF-GO and 64% for SF-G determined by GFP expression. The transduced cells were subsequently selected for 36 h in 10 À6 M of ouabain. Unmodified and SF-G-transduced cells were almost completely eliminated, while 38% of the SF-GOtransduced population survived selection, resulting in a 93% recovery rate of SF-GO-expressing cells (Figure 3b) . A 3-week culture of SF-GO-transduced and -selected cells did not show any alteration in morphology or proliferation rate compared to unmodified and GFP-transduced controls (Figure 3c ). In summary, stable, long-term expression of OuaSelect was achievable and correlated with ouabain resistance.
Transduction and selection of primary lymphocytes
Adoptive immunotherapy with gene-modified T cells is a promising therapeutic approach for various indications. 
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In the first two rows, the native human Na + /K + -ATPase a1 amino-acid sequence Q118-N129 and the corresponding rat sequence are shown numbered according to the human a1 subunit. Below, mutated human a1 constructs are shown. Amino acids shared with the native human protein are marked as (À). In the right column, genes conferring resistance to 10 À5 M ouabain to transiently transfected HeLa cells are labeled with (+), while genes not conferring resistance are labeled (À). The minimal alterations required for resistance is marked in bold. (Figure 5a ). The mean yield of SF-GO-transduced and -selected cells was 81.9%. The SF-GO expression level was very similar among donors and showed only a small increase in the selected populations compared to the unselected SF-GO populations measured by mean GFP fluorescence intensity (MFI; Figure 5b) . Moreover, the expression of GFP-OuaSelect did not influence the proliferation rate of primary lymphocytes in the 2-week culture (Figure 5c) . A cell subset analysis of the transduced and selected lymphocyte populations is found in Table 2 . The effect of ouabain exposure on cell proliferation was investigated on SF-GO-transduced primary lymphocytes from two additional donors. Ouabain exposure did not appear to influence the cell proliferation rate, as measured by the ratio of proliferating cells during selection compared to unmodified and SF-GO-transduced cell populations in normal growth medium (Figure 5d ). In summary, functional expression of OuaSelect was achieved in primary cells, allowing efficient selection of gene-modified cells without apparent toxicity.
Discussion
We report here the development and characterization of an ouabain-resistant human Na + /K + -ATPase a1 mutant and describe the feasibility of using this gene as a selection marker. To our knowledge, this is the first report in which highly efficient selection of genemodified cells has been achieved with a resistance gene of human origin within 48 h of drug exposure.
The ouabain selection regimen developed by our group combines advantages of drug-resistance selection with those of surface marker cell sorting. 22 First, analogous to drug-resistance selection, the efficiency is high. A 499% pure population of gene-modified cells could be obtained with high a yield. Second, a unique feature is the rapid induction of cell death by ouabain. The Na + / K + -ATPase maintains the electrochemical gradients for Na + and K + across the plasma membrane. Blocking the pumping activity of the enzyme by high concentrations of ouabain immediately disrupts the ion concentration gradients, leading to subsequent induction of cell death. 30 Third, akin to drug-resistance selection in general, ouabain selection is highly cost-effective compared to cell sorting under GMP that is necessary for selection regimens depending on surface marker expression. Fourth, unlike most drug-resistance selection regimens, ouabain shows no sign of toxicity other than through its specific inhibition of Na + /K + -ATPase activity. 20 Moreover, cardiac glycosides have the additional advantage of a history of safe administration in the clinical setting. Fifth, since the ouabain-resistant rat gene previously reported 22 is incompatible with clinical gene therapy due to the problem of immunogenicity, the development of a human ouabain selection marker greatly reduces such risks. The human OuaSelect protein is unlikely to cause major immunogenicity concerns, although immune reactions to the altered amino acids cannot be ruled out. Such risks are comparable to the use of cell surface marker genes, where allelic polymorphism occurs. Further studies are needed to clarify if such an effect would be observed in the clinical setting and this is under investigation. 
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The L799C mutation introduced into the rat a1-subunit to increase ouabain resistance 23 did not function in the context of the human-rat chimeric setting. Furthermore, we constructed a human a1 with the L800C substitution (equivalent to the L799C mutation in the rat protein) in addition to Q118R and N129D (a1Q118R/ N129D/L800C) and assessed ouabain resistance of this construct in a transient transfection assay. We found no augmentation of resistance with this construct relative to the a1Q118R/N129D mutant (data not shown). Thus, the mutations increasing ouabain resistance clearly are dependent also upon the environment into which they are introduced.
The level of a1 Q118R/N129D required at the cell surface to generate resistance to ouabain is not known, but the GFP-OuaSelect vector allowed for a highly correlated positive identification and selection of transduced cells. The 38% cell survival after selection of Jurkat cells corresponded to the 41% transduction rate estimated by GFP expression. The results indicated that 93% of cells expressing OuaSelect were protected from ouabaininduced cell death. For primary human lymphocytes, a yield of 82% was achieved. This is a high recovery rate compared to what is achievable with magnetic beads, since magnetic bead cell sorting is associated with, on an average, 50% loss of the gene-modified cells in the sorting process. 16, 31 However, since the recovery is dependent on the surface marker used, the target cell expression level and the cell separation systems available, higher recovery rates have be achieved. 32 The OuaSelect-transduced cells with a likely chimeric expression of endogenous and ouabain-resistant a1 subunits in the plasma membrane appeared to maintain the functional ability of Na + and K + transport without any evident toxicity. OuaSelect-transduced cells also proliferated with the same rate as unmodified controls. Moreover, the protein expression level of GFP-OuaSelect obtained from transient transfection or transduction was similar despite a great difference in transgene copy number per cell. This is probably related to a highly regulated a1 protein expression level, also accounting for the very low fluorescence intensity observed for GFP-OuaSelect compared to GFP. Furthermore, it could explain why selected GFP-OuaSelect-transduced cell populations never reached 100% GFP + cells. For instance, the selected primary lymphocyte populations were 91.5-99.4% GFP + . False-positive selection would be a less likely explanation, since more than 99% of cells not expressing OuaSelect were eliminated.
Among many relevant and promising approaches, T-cell suicide gene therapy in association with allogeneic hematopoietic stem cell transplantation is a potential target application for OuaSelect. Therefore, we also tested the possibility to transduce and select primary human lymphocytes using OuaSelect. Our results show that lymphocytes could be efficiently transduced and Rapid and efficient cell selection with OuaSelect A Treschow et al selected using the SF91-GFP-OuaSelect vector and that the selection procedure eliminated 499% of unmodified cells within 48 h of ouabain exposure. Of note, the GFP control vector provided higher transduction rates than the GFP-OuaSelect vector. Vector size is known to influence the transduction rate of retrovirus vector constructs and could therefore explain the lower transduction rates for GFP-OuaSelect. Loss of GFPOuaSelect-expressing cells due to toxicity as an alternative explanation cannot be neglected, but there was no difference in cell number between GFP-OuaSelecttransduced and -expanded cells and their unmodified counterparts. No significant differences in T-cell subsets or T cell to natural killer (NK) cell ratios were observed, besides inter-donor variation. Small effects on lymphocyte populations from transduction and selection could be observed for both GFP and GFP-OuaSelect, but varied between donors. In summary, we have developed a human ouabainresistant gene that allows efficient cell purification in a rapid and cost-efficient manner. Selection was compatible with several human cell lines derived from different CD3  96  95  98  96  96  94  97  96  77  68  78  67  CD4  47  41  44  50  40  46  47  60  26  26  28  24  CD8  44  53  54  45  56  43  45  30  44  38  46  35  CD56  2  2  1  3  2  1  1  2  19  18  19  30 Cells obtained from buffy coat preparations of three healthy donors were stimulated with CD3/CD28-coated beads for the initial 3 days in culture. They were subsequently transduced on days 4 and 5 by virus preloading technique with SF91-GFP-wpre (SF-G) or SF91-GFPOuaSelect-wpre (SF-GO). Unmodified counterparts (Contr) were cultured in parallel. Samples from the end products of the 13-to 14-day cultures, including SF-GO-transduced cells selected in 10 À6 M ouabain for 48 h (Sel) were analyzed by flow cytometry for CD3, CD4, CD8 and CD56 expression. The numbers in the table represent percents of total viable cells using a FSC/SSC gate. For simplicity, CD3
+ cells are shown as CD56.
Rapid and efficient cell selection with OuaSelect A Treschow et al tissues, in addition to primary lymphocytes. Notably, only two amino-acid substitutions were sufficient to confer resistance to cell death induced by 10
Our experiments demonstrated that highly pure gene-modified cell populations could be achieved within 48 h of selection. OuaSelect uniquely combines efficient and cost-effective selection, a feature of currently used drug selection procedures, with speed and the potential clinical feasibility that previously has been limited to more costly cell marker selection techniques. While its potential use in clinical gene transfer protocols will require further examination both in vitro and in vivo, this system also offers an attractive approach for purification of gene-modified cells in vitro.
Materials and methods
Cells and cell lines
HeLa, Jurkat, U2OS, the retrovirus-packaging cell line PG13 were obtained from ATCC (Manassas, VA, USA). Phoenix GP, a packaging cell line for retrovirus production was also obtained from ATCC with permission from Gary Nolan (Stanford University, Stanford, CA, USA). Cells were cultured in complete medium (Dulbecco's modified Eagle's medium (DMEM) supplemented with glutamax, pyruvate and 10% heat-inactivated fetal bovine serum (FBS), all from Gibco, Grand Island, NY, USA), except Jurkat cells that were cultured in RPMI 1640 (Gibco) supplemented with 10% FBS. Primary human cells from buffy coat preparations, obtained with local ethical approval, were separated by lymphoprep (Lymphoprep, Nygaard, Norway) as described previously 33 and seeded at a density of 2 Â 10 6 cells ml À1 in culture medium consisting of CellGro (CellGenix, Freiburg, Germany), 5% human serum (Biowitthaker, Walksville, MD, USA) and 500 IU ml À1 of IL-2 (Proleukin, Chiron, Amsterdam, The Netherlands). The cells were stimulated with T-cell expansion anti-CD3/CD28T cell beads (Dynal Biotech, Oslo, Norway) for the first 3 days in culture, after which cells were kept at a density of 1 Â 10 6 cells ml
À1
. The medium was changed every 1-3 days and IL-2 was added to the cultures daily.
Gene constructs and plasmids
A human Na + /K + -ATPase a1 plasmid (phNKAa1) was kindly provided by Jerry Lingrel (University of Cincinnati, Cincinnati, OH, USA). The peGFP-OuaR and the peGFP-hNKAa1 plasmids contain XbaI sites located 3 0 to the stop codon and have been previously described. 22 The 3 0 -end chimeric genes were made by substitution of the PflMI-XbaI, PflMI-PpuMI and PpuMI-XbaI fragments in the hNKAa1 with the homologous fragments of OuaR, respectively. The additional crossover points at position 390 and 900 bp were generated by PCR. Detailed information regarding cloning strategies can be obtained upon request. The chimeric, full-length genes were cloned with the TOPO cloning kit (Invitrogen, Carlsbad, CA, USA) and subsequently excised from the TOPO vectors with HindIII and inserted into the HindIII site of peGFP-C1 or peGFP-C3 (Clontech, Palo Alto, CA, USA). Sequences were confirmed by restriction enzyme mapping and sequencing.
Single, double, triple or quadruple point mutations were introduced into the human a1 gene by PCR. The following primers were used together with hNKAa1-3 0 . HindIII rev and EGFP-3 0 fw to make overlapping segments, which were joined and amplified by PCR:
0 . The full-length genes were cloned with the TOPO cloning kit. The mutations were introduced by substituting the AccI fragment of native a1 in pGFPhNKAa1. Codon optimization of OuaSelect was performed by GeneArt (Regensburg, Germany) to increase RNA stability and translation efficiency. The optimized gene was used in the HeLa, U2OS and primary lymphocyte experiments.
For generation of retroviral constructs, SF91b-eGFP-wpre (SF-G) was kindly provided by Christopher Baum (Hannover Medical School, Hannover, Germany). EGFP-OuaSelect was cloned as a BsrGI-SalI fragment into SF91b-eGFP-wpre to make SF91b-eGFP-OuaSelectwpre (SF-GO). A Kozak translation initiation sequence was introduced to the OuaSelect gene by PCR with a 5 0 primer containing a consensus translation initiation site (GCCACCATGG). The gene was cloned into the HindIII site in pSF91b-wpre (SF-O). 34 
Retroviral vector production
Phoenix GP cells were seeded in six-well plates, and were transfected the following day using FuGENE6 (Roche, Mannheim, Germany) with 3.75 mg of vector plasmid and 0.75 mg of pMDG encoding the vesicular stomatitis virus glycoprotein (VSV-G) and kindly provided by Didier Trono (University of Geneva, Geneva, Switzerland). PG13 producer cells were prepared by five daily repetitions of transduction using the Phoenix GP supernatants with the addition of 4 mg ml À1 of Polybrene. The PG13 supernatants were harvested, passed through 0.45 mm filters and frozen at À70 1C. The titers were 2-5 Â 10 5 ouabain-resistant colony-forming units per ml, as assessed on HeLa cells.
Gene transfer by transfection and transduction
HeLa and U2OS cells were transfected in six-well plates using FuGENE6 according to the manufacturer's instructions. Jurkat cells were transduced by centrifugation in the supernatants at 1000 g for 2 h with an MOI of 1.5 and 8 mg ml À1 of Polybrene. For the dose-response assay, GFP-positive cells were sorted on an FACS Diva (Becton Dickinson, Franklin Lakes, NJ, USA).
Transduction and selection of human primary lymphocytes
Human lymphocytes were transduced at an MOI of three on days 4-5, using a virus preloading technique. 22 Cells
Rapid and efficient cell selection with OuaSelect A Treschow et al were then incubated in the preloaded wells for 24 h with 4 mg ml À1 of Polybrene. The 48-h selection started on days 7-9 and was terminated by two times washing in PBS (Gibco). The final assessment of cells by flow cytometry and Trypan blue dye exclusion was performed on days 12-14.
Flow cytometry
For analysis of lymphocyte subsets, four-colored fluorescent analysis was performed according to standard procedures. In brief, 10 5 cells per tube were mixed with appropriate concentration of directly conjugated monoclonal antibodies (CD3-PE, CD4-PerCP, CD8-APC, and CD56-APC) (Becton Dickinson). After incubation for 30 min at 4 1C, cells were washed in PBS, pending analysis. All samples were analyzed by setting appropriate FSC/SSC gates around the lymphocyte populations.
For cell cycle analysis, lymphocytes were isolated as described, cultured and transduced twice with the SF-GO supernatant as described previously. 35 The transduction rate was 24.2 and 19.0% for the two donors, assessed as above. Cells were split into continuous culture or selection in 10 À6 M ouabain and analyzed on the third day of selection. The cell cycle analysis was performed by flow cytometry as described previously. 36 Viable cells were discriminated in a FSC/SSC plot and PI fluorescence was collected using linear amplification. Cells in cell cycle were defined as a percentage of viable cells in the S+G 2 /M phases in DNA histograms.
Ouabain selection and cell viability assays
Ouabain (Sigma, St Louis, MO, USA) was dissolved in water as a stock solution of 10 À2 M and added to the culture medium. The selection was terminated by washing the cells twice in PBS. GFP expression and cell viability was assessed by fluorescence microscope. In the dose-response experiment, cell survival was quantified in a spectrophotometer using the WST-1 Tetrazolium colorimetric cell proliferation reagent (Roche) according to the manufacturer's instructions. Quantification of Jurkat cells and lymphocytes was made using Trypan blue dye exclusion. Flow cytometric analysis of GFP expression was performed using FACS Calibur with CellQuest software (Becton Dickinson).
